Camel Whey Protein Disrupts the Cross-Talk Between PI3K and BCL-2 Signals and Mediates Apoptosis in Primary Acute Myeloid Leukemia Cells

References

• Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, and McCubrey JA. : Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 9, 1333–1349, 2009.
   Web of Science ®Google Scholar
• Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, and Willems L. : Role of the PI3K/AKT and mTOR signalling pathways in acute myeloid leukemia. Haematologica 95, 819–828, 2010.
   PubMed Web of Science ®Google Scholar
• Oltvai ZN, Milliman CL, and Korsmeyer SJ. : Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609–619, 1993.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, et al. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52, 6940–6944, 1992.
   PubMed Web of Science ®Google Scholar
• Delbridge A, and Strasser A. : The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 7, 1071–1080, 2015.
   Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681, 2005.
   PubMed Web of Science ®Google Scholar
• Park CM, Bruncko M, Adickes J, Bauch J, Ding H, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51, 6902–6915, 2008.
   PubMed Web of Science ®Google Scholar
• Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11, 1149–1159, 2010.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Camidge DR, De Oliveira MR, Bonomi P, Gandara D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29, 909–916, 2011.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30, 488–496, 2012.
   PubMed Web of Science ®Google Scholar
• Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, et al. Programmed anuclear cell death delimits platelet life span. Cell 128, 1173–1186, 2007.
   PubMed Web of Science ®Google Scholar
• Debrincat M, Pleines I, Lebois M, Lane R, Holmes M, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis 6, e1721, 2015.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19, 202–208, 2013.
   PubMed Web of Science ®Google Scholar
• Vandenberg CJ, and Cory S. : ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121, 2285–2288, 2013.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst Schetelig BJ, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17, 768–778, 2016.
   PubMed Web of Science ®Google Scholar
• Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, et al. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia 28, 1160–1557, 2014.
   Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2, 178–184, 2015.
   Web of Science ®Google Scholar
• Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4, 362–375, 2014.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 10, 1106–1117, 2016.
   Web of Science ®Google Scholar
• Deeks ED. : Venetoclax: first global approval. Drugs 76, 979–987, 2016.
   PubMed Web of Science ®Google Scholar
• Bose P, Vachhani P, and Cortes JE. : Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol 18, 17, 2017.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375–388, 2006.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, and Grant S. : Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism . Cancer Res 73, 1340–1351, 2013.
   PubMed Web of Science ®Google Scholar
• Maurer U, Charvet C, Wagman AS, Dejardin E, and Green DR. : Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21, 749–760, 2006.
   PubMed Web of Science ®Google Scholar
• Mills JR, Hippo Y, Robert F, Chen SM, Malina A, et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105, 10853–10858, 2008.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, et al. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica 100, 1553–1563, 2015.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang Z, Qu X, Zhu X, Zhao L, et al. Roles of STAT3 in leukemia (Review). Int J Oncol 53, 7–20, 2018.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Nepstad I, Hauge M, Hatfield KJ, and Reikvam H. : STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Rev Hematol 8, 29–41, 2015.
   PubMed Web of Science ®Google Scholar
• Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, and Tweardy DJ. : Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117, 5701–5709, 2011.
   PubMed Web of Science ®Google Scholar
• Sayed LH, Badr G, Omar HM, Abd El-Rahim AM, and Mahmoud MH. : Camel whey protein improves oxidative stress and histopathological alterations in lymphoid organs through Bcl-XL/Bax expression in a streptozotocin-induced type 1 diabetic mouse model. Biomed Pharmacother 88, 542–552, 2017.
   PubMed Web of Science ®Google Scholar
• Badr G, Mohany M, and Metwalli A. : Effects of undenatured whey protein supplementation on CXCL12- and CCL21-mediated B and T cell chemotaxis in diabetic mice. Lipids Health Dis 10, 203, 2011.
   PubMed Web of Science ®Google Scholar
• Badr G. : Camel whey protein enhances diabetic wound healing in a streptozotocin-induced diabetic mouse model: the critical role of β-Defensin-1, -2 and -3. Lipids Health Dis 12, 46, 2013.
   PubMed Web of Science ®Google Scholar
• Badr G. : Supplementation with undenatured whey protein during diabetes mellitus improves the healing and closure of diabetic wounds through the rescue of functional long-lived wound macrophages. Cell Physiol Biochem 29, 571–582, 2012.
   PubMed Web of Science ®Google Scholar
• Badr G, Saad H, Waly H, Hassan K, Abdel-Tawab H, et al. Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cell Immunol 263, 31–40, 2010.
   PubMed Web of Science ®Google Scholar
• Badr G, and Mohany M. : Maternal perinatal undernutrition attenuates T-cell function in adult male rat offspring. Cell. Cell Physiol Biochem 27, 381–390, 2011.
   PubMed Web of Science ®Google Scholar
• Sayed D, Badr G, Maximous D, Mikhail NN, Abu-Tarboush F, and Alhazza IM. : HLA-G and its relation to proliferation index in detection and monitoring breast cancer patients. Tissues Antigens 75, 40–47, 2010.
   PubMedGoogle Scholar
• Badr G, Al-Sadoon MK, El-Toni AM, and Daghestani M. : Walterinnesia aegyptia venom combined with silica nanoparticles enhances the functioning of normal lymphocytes through PI3K/AKT, NFκB and ERK signaling. Lipids Health Dis 11, 27, 2012.
   PubMed Web of Science ®Google Scholar
• Badr G, Mahmoud Mh K, Farhat K, Waly H, Al-Abdin OZ, and Rabah DM. : Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling. Lipids Health Dis 12, 27, 2013.
   PubMed Web of Science ®Google Scholar
• Hozzein WN, Badr G, Al Ghamdi AA, Sayed A, Al-Waili NS, and Garraud O. : Topical application of propolis enhances cutaneous wound healing by promoting TGF-beta/Smad-mediated collagen production in a streptozotocin-induced type I diabetic mouse model. Cell Physiol Biochem 37, 940–954, 2015.
   PubMed Web of Science ®Google Scholar
• Badr G, Garraud O, Daghestani M, Al-Khalifa MS, and Richard Y. : Human breast carcinoma cells are induced to apoptosis by samsum ant venom through an IGF-1-dependant pathway, PI3K/AKT and ERK signaling. Cell Immunol 273, 10–16, 2012.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, et al. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Res 78, 3075–3086, 2018.
   PubMed Web of Science ®Google Scholar
• Mussai FJ, Yap C, Mitchell C, and Kearns P. : Challenges of clinical trial design for targeted agents against pediatric leukemias. Front Oncol 4, 374, 2014.
   PubMed Web of Science ®Google Scholar
• Martínez-García D, Manero-Rupérez N, Quesada R, Korrodi-Gregório L, and Soto-Cerrato V. : Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev 39, 887–909, 2019.
   Web of Science ®Google Scholar
• Xu DC, Arthurton L, and Baena-Lopez LA. : Learning on the Fly: The Interplay between Caspases and Cancer. Biomed Res Int 2018, 5473180, 2018.
   PubMed Web of Science ®Google Scholar
• Nepstad I, Hatfield KJ, Tvedt THA, Reikvam H, and Bruserud O. : Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. Cancers (Basel) 10, 2018. doi:10.3390/cancers10090332
   PubMed Web of Science ®Google Scholar
• Herschbein L, and Liesveld JL. : Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. Blood Rev 32, 235–248, 2018.
   PubMed Web of Science ®Google Scholar
• Mesbahi Y, Zekri A, Ghaffari SH, Tabatabaie PS, Ahmadian S, and Ghavamzadeh A. : Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species. Eur J Pharmacol 834, 65–76, 2018.
   PubMed Web of Science ®Google Scholar
• Yamaguchi R, Lartigue L, and Perkins G. : Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther S0163–7258, 30191–30193, 2018.
   Google Scholar
• Sharma P, and Pollyea DA. : Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. Curr Hematol Malig Rep 13, 256–264, 2018.
   PubMed Web of Science ®Google Scholar
• Kulsoom B, Shamsi TS, Afsar NA, Memon Z, Ahmed N, and Hasnain SN. : Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: Are we ready for Bcl-2-directed therapy? Cancer Manag Res 10, 403–416, 2018.
   PubMed Web of Science ®Google Scholar
• Su Y, Li X, Ma J, Zhao J, Liu S, et al. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148, 13–26, 2018.
   PubMed Web of Science ®Google Scholar